Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The company had earlier announced about the approval received from the MHRA for Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Subscribe To Our Newsletter & Stay Updated